blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2245070

EP2245070 - 1B20 PCSK9 ANTAGONISTS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  12.06.2015
Database last updated on 16.07.2024
Most recent event   Tooltip22.06.2018Lapse of the patent in a contracting state
New state(s): MK		published on 25.07.2018  [2018/30]
Applicant(s)For all designated states
Merck Sharp & Dohme Corp.
126 East Lincoln Avenue
Rahway, NJ 07065-0907 / US
[2014/32]
Former [2012/33]For all designated states
Merck Sharp & Dohme Corp.
126 East Lincoln Avenue
Rahway NJ 07065-0907 / US
Former [2010/44]For all designated states
Merck Sharp & Dohme Corp.
126 East Lincoln Avenue
Rahway, NJ 07065 / US
Inventor(s)01 / CONDRA, Jon, H.
126 East Lincoln Avenue
Rahway New Jersey 07065-0907 / US
02 / CUBBON, Rose, M.
126 East Lincoln Avenue
Rahway New Jersey 07065-0907 / US
03 / HAMMOND, Holly, A.
126 East Lincoln Avenue
Rahway New Jersey 07065-0907 / US
04 / MCCABE, Timothy
126 East Lincoln Avenue
Rahway New Jersey 07065-0907 / US
05 / PANDIT, Shilpa
126 East Lincoln Avenue
Rahway New Jersey 07065-0907 / US
06 / PETERSON, Laurence, B.
126 East Lincoln Avenue
Rahway New Jersey 07065-0907 / US
07 / SANTORO, Joseph, C.
126 East Lincoln Avenue
Rahway New Jersey 07065-0907 / US
08 / SITLANI, Ayesha
126 East Lincoln Avenue
Rahway New Jersey 07065-0907 / US
09 / WOOD, Dana, D.
126 East Lincoln Avenue
Rahway New Jersey 07065-0907 / US
10 / MACH, Henryk
126 East Lincoln Avenue
Rahway New Jersey 07065-0907 / US
11 / YODER, Heidi
126 East Lincoln Avenue
Rahway New Jersey 07065-0907 / US
12 / GREGORY, Sonia, M.
126 East Lincoln Avenue
Rahway New Jersey 07065-0907 / US
13 / BLUE, Jeffrey, T.
126 East Lincoln Avenue
Rahway New Jersey 07065-0907 / US
14 / WANG, Kevin
126 East Lincoln Avenue
Rahway New Jersey 07065-0907 / US
15 / LUO, Peter
126 East Lincoln Avenue
Rahway New Jersey 07065-0907 / US
16 / NAWROCKI, Denise, K.
126 East Lincoln Avenue
Rahway New Jersey 07065-0907 / US
17 / ZHONG, Pingyu
126 East Lincoln Avenue
Rahway New Jersey 07065-0907 / US
18 / DONG, Feng
126 East Lincoln Avenue
Rahway New Jersey 07065-0907 / US
19 / LI, Yan
126 East Lincoln Avenue
Rahway New Jersey 07065-0907 / US
 [2010/44]
Representative(s)Hussain, Deeba, et al
Merck Sharp & Dohme (UK) Limited
120 Moorgate
London EC2M 6UR / GB
[N/P]
Former [2010/44]Hussain, Deeba, et al
Merck Sharp & Dohme Limited Hertford Road Hoddesdon
Hertfordshire EN11 9BU / GB
Application number, filing date09707156.706.02.2009
[2010/44]
WO2009US33369
Priority number, dateUS20080063980P07.02.2008         Original published format: US 63980 P
[2014/13]
Former [2010/44]US2008006398007.02.2008
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2009100318
Date:13.08.2009
Language:EN
[2009/33]
Type: A1 Application with search report 
No.:EP2245070
Date:03.11.2010
Language:EN
The application published by WIPO in one of the EPO official languages on 13.08.2009 takes the place of the publication of the European patent application.
[2010/44]
Type: B1 Patent specification 
No.:EP2245070
Date:06.08.2014
Language:EN
[2014/32]
Search report(s)International search report - published on:EP13.08.2009
ClassificationIPC:C07K16/40, C12N9/64, A61K39/395, C12N15/13, A61P3/06
[2010/44]
CPC:
C07K16/40 (EP,US); A61P3/00 (EP); A61P3/06 (EP);
A61P9/10 (EP); C12N9/6424 (EP,US); A61K2039/505 (EP,US);
C07K2317/56 (EP,US); C07K2317/565 (EP,US); C07K2317/76 (EP,US);
C07K2317/77 (EP,US); C07K2317/92 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2010/44]
TitleGerman:1B20 PCSK9 ANTAGONISTEN[2014/10]
English:1B20 PCSK9 ANTAGONISTS[2010/44]
French:ANTAGONISTES DE 1B20 PCSK9[2010/44]
Former [2010/44]1B20-PCSK9-ANTAGONISTEN
Entry into regional phase07.09.2010National basic fee paid 
07.09.2010Designation fee(s) paid 
07.09.2010Examination fee paid 
Examination procedure19.08.2010Amendment by applicant (claims and/or description)
07.09.2010Examination requested  [2010/44]
24.10.2012Despatch of a communication from the examining division (Time limit: M06)
11.06.2013Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
09.08.2013Reply to a communication from the examining division
27.08.2013Despatch of a communication from the examining division (Time limit: M04)
17.12.2013Reply to a communication from the examining division
06.03.2014Communication of intention to grant the patent
27.06.2014Fee for grant paid
27.06.2014Fee for publishing/printing paid
27.06.2014Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  24.10.2012
Opposition(s)07.05.2015No opposition filed within time limit [2015/29]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
09.08.2013Request for further processing filed
09.08.2013Full payment received (date of receipt of payment)
Request granted
23.08.2013Decision despatched
Fees paidRenewal fee
08.02.2011Renewal fee patent year 03
07.02.2012Renewal fee patent year 04
07.02.2013Renewal fee patent year 05
07.02.2014Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU06.02.2009
AT06.08.2014
BE06.08.2014
CY06.08.2014
CZ06.08.2014
DK06.08.2014
EE06.08.2014
ES06.08.2014
FI06.08.2014
HR06.08.2014
IT06.08.2014
LT06.08.2014
LV06.08.2014
MC06.08.2014
MK06.08.2014
MT06.08.2014
NL06.08.2014
PL06.08.2014
RO06.08.2014
SE06.08.2014
SI06.08.2014
SK06.08.2014
TR06.08.2014
BG06.11.2014
NO06.11.2014
GR07.11.2014
IS06.12.2014
PT09.12.2014
IE06.02.2015
LU06.02.2015
CH28.02.2015
LI28.02.2015
[2018/30]
Former [2017/40]HU06.02.2009
AT06.08.2014
BE06.08.2014
CY06.08.2014
CZ06.08.2014
DK06.08.2014
EE06.08.2014
ES06.08.2014
FI06.08.2014
HR06.08.2014
IT06.08.2014
LT06.08.2014
LV06.08.2014
MC06.08.2014
MT06.08.2014
NL06.08.2014
PL06.08.2014
RO06.08.2014
SE06.08.2014
SI06.08.2014
SK06.08.2014
TR06.08.2014
BG06.11.2014
NO06.11.2014
GR07.11.2014
IS06.12.2014
PT09.12.2014
IE06.02.2015
LU06.02.2015
CH28.02.2015
LI28.02.2015
Former [2017/03]AT06.08.2014
BE06.08.2014
CY06.08.2014
CZ06.08.2014
DK06.08.2014
EE06.08.2014
ES06.08.2014
FI06.08.2014
HR06.08.2014
IT06.08.2014
LT06.08.2014
LV06.08.2014
MC06.08.2014
MT06.08.2014
NL06.08.2014
PL06.08.2014
RO06.08.2014
SE06.08.2014
SI06.08.2014
SK06.08.2014
BG06.11.2014
NO06.11.2014
GR07.11.2014
IS06.12.2014
PT09.12.2014
IE06.02.2015
LU06.02.2015
CH28.02.2015
LI28.02.2015
Former [2016/32]AT06.08.2014
BE06.08.2014
CY06.08.2014
CZ06.08.2014
DK06.08.2014
EE06.08.2014
ES06.08.2014
FI06.08.2014
HR06.08.2014
IT06.08.2014
LT06.08.2014
LV06.08.2014
MC06.08.2014
NL06.08.2014
PL06.08.2014
RO06.08.2014
SE06.08.2014
SI06.08.2014
SK06.08.2014
BG06.11.2014
NO06.11.2014
GR07.11.2014
IS06.12.2014
PT09.12.2014
IE06.02.2015
LU06.02.2015
CH28.02.2015
LI28.02.2015
Former [2016/07]AT06.08.2014
CY06.08.2014
CZ06.08.2014
DK06.08.2014
EE06.08.2014
ES06.08.2014
FI06.08.2014
HR06.08.2014
IT06.08.2014
LT06.08.2014
LV06.08.2014
MC06.08.2014
NL06.08.2014
PL06.08.2014
RO06.08.2014
SE06.08.2014
SI06.08.2014
SK06.08.2014
BG06.11.2014
NO06.11.2014
GR07.11.2014
IS06.12.2014
PT09.12.2014
IE06.02.2015
LU06.02.2015
BE28.02.2015
CH28.02.2015
LI28.02.2015
Former [2015/50]AT06.08.2014
CY06.08.2014
CZ06.08.2014
DK06.08.2014
EE06.08.2014
ES06.08.2014
FI06.08.2014
HR06.08.2014
IT06.08.2014
LT06.08.2014
LV06.08.2014
MC06.08.2014
NL06.08.2014
PL06.08.2014
RO06.08.2014
SE06.08.2014
SI06.08.2014
SK06.08.2014
BG06.11.2014
NO06.11.2014
GR07.11.2014
IS06.12.2014
PT09.12.2014
LU06.02.2015
BE28.02.2015
CH28.02.2015
LI28.02.2015
Former [2015/47]AT06.08.2014
CY06.08.2014
CZ06.08.2014
DK06.08.2014
EE06.08.2014
ES06.08.2014
FI06.08.2014
HR06.08.2014
IT06.08.2014
LT06.08.2014
LV06.08.2014
MC06.08.2014
NL06.08.2014
PL06.08.2014
RO06.08.2014
SE06.08.2014
SK06.08.2014
BG06.11.2014
NO06.11.2014
GR07.11.2014
IS06.12.2014
PT09.12.2014
LU06.02.2015
BE28.02.2015
CH28.02.2015
LI28.02.2015
Former [2015/46]AT06.08.2014
CY06.08.2014
CZ06.08.2014
DK06.08.2014
EE06.08.2014
ES06.08.2014
FI06.08.2014
HR06.08.2014
IT06.08.2014
LT06.08.2014
LV06.08.2014
MC06.08.2014
NL06.08.2014
PL06.08.2014
RO06.08.2014
SE06.08.2014
SK06.08.2014
BG06.11.2014
NO06.11.2014
GR07.11.2014
IS06.12.2014
PT09.12.2014
LU06.02.2015
BE28.02.2015
Former [2015/44]AT06.08.2014
CY06.08.2014
CZ06.08.2014
DK06.08.2014
EE06.08.2014
ES06.08.2014
FI06.08.2014
HR06.08.2014
IT06.08.2014
LT06.08.2014
LV06.08.2014
NL06.08.2014
PL06.08.2014
RO06.08.2014
SE06.08.2014
SK06.08.2014
BG06.11.2014
NO06.11.2014
GR07.11.2014
IS06.12.2014
PT09.12.2014
LU06.02.2015
BE28.02.2015
Former [2015/30]AT06.08.2014
CY06.08.2014
CZ06.08.2014
DK06.08.2014
EE06.08.2014
ES06.08.2014
FI06.08.2014
HR06.08.2014
IT06.08.2014
LT06.08.2014
LV06.08.2014
NL06.08.2014
PL06.08.2014
RO06.08.2014
SE06.08.2014
SK06.08.2014
BG06.11.2014
NO06.11.2014
GR07.11.2014
IS06.12.2014
PT09.12.2014
BE28.02.2015
Former [2015/23]AT06.08.2014
CY06.08.2014
CZ06.08.2014
DK06.08.2014
EE06.08.2014
ES06.08.2014
FI06.08.2014
HR06.08.2014
IT06.08.2014
LT06.08.2014
LV06.08.2014
NL06.08.2014
PL06.08.2014
RO06.08.2014
SE06.08.2014
SK06.08.2014
BG06.11.2014
NO06.11.2014
GR07.11.2014
IS06.12.2014
PT09.12.2014
Former [2015/22]AT06.08.2014
CY06.08.2014
DK06.08.2014
ES06.08.2014
FI06.08.2014
HR06.08.2014
IT06.08.2014
LT06.08.2014
LV06.08.2014
NL06.08.2014
PL06.08.2014
RO06.08.2014
SE06.08.2014
BG06.11.2014
NO06.11.2014
GR07.11.2014
IS06.12.2014
PT09.12.2014
Former [2015/12]AT06.08.2014
CY06.08.2014
ES06.08.2014
FI06.08.2014
HR06.08.2014
LT06.08.2014
LV06.08.2014
NL06.08.2014
PL06.08.2014
SE06.08.2014
BG06.11.2014
NO06.11.2014
GR07.11.2014
IS06.12.2014
PT09.12.2014
Former [2015/11]CY06.08.2014
ES06.08.2014
FI06.08.2014
LT06.08.2014
PL06.08.2014
SE06.08.2014
BG06.11.2014
NO06.11.2014
GR07.11.2014
PT09.12.2014
Former [2015/10]ES06.08.2014
FI06.08.2014
LT06.08.2014
SE06.08.2014
BG06.11.2014
NO06.11.2014
Former [2015/09]FI06.08.2014
LT06.08.2014
SE06.08.2014
Former [2015/08]LT06.08.2014
Cited inInternational search[X]WO0157081  (MILLENNIUM PHARM INC [US], et al) [X] 1-23,27-38 * page 49, line 20 - page 53, line 28 * * figure 2 *;
 [X]US2002045571  (LIU JUN [US], et al) [X] 24,25 * paragraph [0023]; figure 3; example 3 *;
 [A]WO2004018649  (US ARMY MEDICAL RES INST OF IN [US], et al) [A] * sequences 17,20 *;
 [PX]WO2008057459  (MERCK & CO INC [US], et al) [PX] 1-23,27-38 * the whole document *;
 [PX]WO2008057458  (MERCK & CO INC [US], et al) [PX] 1-23,27-38 * the whole document *;
 [PX]WO2008057457  (MERCK & CO INC [US], et al) [PX] 1-23,27-38 * the whole document *;
 [PX]WO2008063382  (MERCK & CO INC [US], et al) [PX] 1-23,27-38 * the whole document *;
 [PX]WO2008086395  (WYETH CORP [US], et al) [PX] 24-26* the whole document, especially examples 8-10, tables 6-8, claims 1-22 *;
 [PX]WO2008125623  (NOVARTIS AG [CH], et al) [PX] 1-23,27-38 * page 2, line 14 - line 33 * * page 7, line 4 - page 8, line 32 * * table 2 * * page 22, line 1 - page 55, line 32 *;
 [PX]WO2008133647  (MERCK & CO INC [US], et al) [PX] 1-23,27-38 * the whole document *;
 [E]WO2009026558  (AMGEN INC [US], et al) [E] 1-11,23,28-30,35-38 * paragraphs [0002] , [0008] - [0020] - [0022] , [0024] , [0027] - [0030] - [0033] , [0037] - [0041] - [0160] , [0161] , [0247] - [0267] - [0296] * * paragraphs [0334] - [0337] - [0357] - [0359]; figures 2-16,26-28; examples 1-41; claims 1-38 *;
 [X]  - LAGACE THOMAS A ET AL, "Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, (20061101), vol. 116, no. 11, ISSN 0021-9738, pages 2995 - 3005, XP002493243 [X] 1-23,27-38 * the whole document, especially page 2996, left column, last 3 lines; page 3002, right column, last 6 lines; page 3003, left column, lines 28-31 and 39-41 *

DOI:   http://dx.doi.org/10.1172/JCI29383
 [XY]  - RASHID S ET AL, "Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC.; US, (20050412), vol. 102, no. 15, ISSN 0027-8424, pages 5374 - 5379, XP002478031 [X] 1-23,30-38 * abstract * * page 5375, column L, paragraph 3 * * page 5378, column R, paragraph 1 * * page 5379, column R, paragraph 3 * [Y] 27-29

DOI:   http://dx.doi.org/10.1073/pnas.0501652102
 [XY]  - ALBORN WILLIAM E ET AL, "Serum proprotein convertase subtilisin Kexin type 9 is correlated directly with serum LDL cholesterol", CLINICAL CHEMISTRY, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY, WASHINGTON, DC, (20071001), vol. 53, no. 10, ISSN 0009-9147, pages 1814 - 1819, XP009104836 [X] 1-23,30-38 * the whole document * [Y] 27-29

DOI:   http://dx.doi.org/10.1373/clinchem.2007.091280
 [Y]  - HORTON ET AL, "Molecular biology of PCSK9: its role in LDL metabolism", TRENDS IN BIOCHEMICAL SCIENCES, ELSEVIER, HAYWARDS, GB, (20070206), vol. 32, no. 2, ISSN 0968-0004, pages 71 - 77, XP002523531 [Y] 27-29 * the whole document, especially page 75, left column, second paragraph *

DOI:   http://dx.doi.org/10.1016/J.TIBS.2006.12.008
 [A]  - LOPEZ ET AL, "PCSK9: An enigmatic protease", BIOCHIMICA AND BIOPHYSICA ACTA. MOLECULAR AND CELL BIOLOGY OFLIPIDS, ELSEVIER, AMSTERDAM, NL, (20080202), vol. 1781, no. 4, ISSN 1388-1981, pages 184 - 191, XP022554055 [A] * the whole document *
 [PX]  - LOPEZ DAYAMI, "Inhibition of PCSK9 as a novel strategy for the treatment of hypercholesterolemia.", DRUG NEWS & PERSPECTIVES 2008 JUL-AUG, (200807), vol. 21, no. 6, ISSN 0214-0934, pages 323 - 330, XP001539306 [PX] 1-23,27-38 * the whole document, especially page 328 under headline "potential PCSK9 inhibitors" *

DOI:   http://dx.doi.org/10.1358/dnp.2008.21.6.1246795
 [X]  - CHEN BEI ET AL, "Influence of histidine on the stability and physical properties of a fully human antibody in aqueous and solid forms", PHARMACEUTICAL RESEARCH, KLUWER ACADEMIC PUBLISHERS, NEW YORK, NY, US, (20031201), vol. 20, no. 12, ISSN 0724-8741, pages 1952 - 1960, XP002386671 [X] 24-26 * the whole document, especially page 1953, left-hand column, 4th full paragraph - right-hand column, first paragraph *

DOI:   http://dx.doi.org/10.1023/B:PHAM.0000008042.15988.c0
 [A]  - AKERS MICHAEL J ET AL, "FORMULATION DEVELOPMENT OF PROTEIN DOSAGE FORMS", PHARMACEUTICAL BIOTECHNOLOGY, KLUWER, DORDRECHT, NL, (20020101), vol. 14, ISSN 1078-0467, pages 47 - 127, XP001537612 [A] * the whole document *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.